| Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
Recent studies have indicated that targeting antigens to XCR1, a chemokine receptor selectively expressed on cross-presenting dendritic cells using antigen fused to XCL1/Lymphotactin, an XCR1 ligand, represents an effective induction of CD8+ T cell response. In this study, we generate a high active form of XCL1 (XCL1-CC3) and investigate in vivo adjuvant efficacy. Wild-type XCL1 (XCL1-WT) have higher cell migration activity and calcium mobilization activity than XCL1-CC3. When intradermally injected with ovalbumin as a model antigen, both XCL1-WT and XCL1-CC3 induced potent CD8+ T cell responses and XCL1-CC3 showed more effective CD8+ T cell-mediated antitumor immunity than XCL1-WT. In addition, XCL1-CC3 enhanced an accumulation of CD103+XCR1+ cross-presenting dendritic cells rather than XCL1-WT. The present results indicate that XCL1-CC3 has potential to induce more efficient CD8+ T cells responses as CTL-inducing vaccine adjuvant than XCL1-WT.
|
